Published in TB and Outbreaks Week, July 25th, 2006
Study 1: Monoclonal antibodies have been developed for the management of SARS and the development of SARS vaccines.
According to a recent review from Japan, "SARS-CoV is a new type of human coronavirus identified as a causative agent of severe acute respiratory syndrome (SARS).
"In this review," Y. Tsunetsugu-Yokota and colleagues at the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.